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Abstract
The chemotherapeutic drug 5-FU is widely used in the treatment of a range of cancers, but resistance to the drug remains a
major clinical problem. Since defects in the mediators of apoptosis may account for chemo-resistance, the identification of
new targets involved in 5-FU-induced apoptosis is of main clinical interest. We have identified the ds-RNA-dependent
protein kinase (PKR) as a key molecular target of 5-FU involved in apoptosis induction in human colon and breast cancer cell
lines. PKR distribution and activation, apoptosis induction and cytotoxic effects were analyzed during 5-FU and 5-FU/IFNa
treatment in several colon and breast cancer cell lines with different p53 status. PKR protein was activated by 5-FU
treatment in a p53-independent manner, inducing phosphorylation of the protein synthesis translation initiation factor eIF-
2a and cell death by apoptosis. Furthermore, PKR interference promoted a decreased response to 5-FU treatment and those
cells were not affected by the synergistic antitumor activity of 5-FU/IFNa combination. These results, taken together,
provide evidence that PKR is a key molecular target of 5-FU with potential relevance in the clinical use of this drug.
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Introduction
The fluoropyrimidine 5-fluorouracil (5-FU) is widely used in the
treatment of a range of cancers including colorectal cancer and
breast tumors [1,2], but resistance to the drug remains a major
clinical problem. The antimetabolite 5-FU is an analogue of uracil
with a fluorine atom at the C5 position of the pyrimidine ring.
Inside cells, 5-FU is converted into different active metabolites,
including fluorodeoxyuridine monophosphate (FdUMP), fluoro-
deoxyuridine triphosphate (FdUTP), and fluorouridine triphos-
phate (FUTP). These metabolites have been implicated in both
global RNA metabolism due to the incorporation of the
ribonucleotide FUMP into RNA, and DNA metabolism due to
thymidylate synthase (TS) inhibition or direct incorporation of
FdUMP into DNA, leading to a wide range of biological effects
which can act as triggers for apoptotic cell death [3,4]. The tumor
suppressor p53 is one molecular target by 5-FU, and as part of its
antitumor activity triggers cell cycle blockage and/or apoptosis.
However, while several reports have demonstrated that 5-FU-
induced apoptosis is dependent on the tumour suppressor p53
protein, apoptosis can also occur in mutant p53 cell lines by a
mechanism still unknown [5,6,7].Since alterations in the mediators
of 5-FU-induced apoptosis may account for chemo resistance, the
identification of new targets involved in the 5-FU-induced
apoptosis is of significant clinical interest.
Interferons (IFN) type I are pleiotropic cytokines with antiviral
and antitumor activities that are widely used in the clinic [8,9]. In
clinical trials and experimental settings the combination of IFNa
with 5-FU has been demonstrated to be superior to 5-FU
administered alone, although the mechanism of this synergistic
effect is still poorly understood [10,11,12,13]. Approximately 35
years ago the double-stranded RNA (dsRNA)-dependent protein
kinase (PKR) was initially identified as an innate immune anti-viral
protein that is induced by the IFN type I [14,15]. Since then, PKR
has been linked to normal cell growth and differentiation,
inflammation, cytokine signaling, and apoptosis, and is involved
in the antiviral and antitumor activities of IFN [16]. Moreover,
altered PKR activity has been shown to play a role in
neurodegenerative diseases and cancer [17,18,19,20]. PKR is a
serine/threonine kinase, characterized by two distinct kinase
activities: autophosphorylation, which represents the activation
reaction, and the phosphorylation of the translation initiation
factor eIF2a [21], which impairs eIF-2 activity, resulting in the
inhibition of protein synthesis [22]. In addition, PKR has a role in
signal transduction and transcriptional control through the IkB/
NF-kB pathway [23,24]. PKR is activated in response to dsRNA
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activated by polyanions such as heparin, dextran sulfate,
chondroitin sulfate, and poly-L-glutamine [25]. Cellular stress
such as arsenite, thapsigargin, H2O2, ethanol and ceramide can
also activate PKR, [26,27] presumably through the PKR-
associated activator PACT/RAX protein [28]. Over-expression
or continued activation of PKR leads to cell death by apoptosis
through the FADD/caspase 8 and mitochondrial APAF/caspase 9
activation pathways [29,30,31].
The aim of this work was to analyze the role of PKR as a
molecular target of 5-FU and the importance of PKR in the
enhanced antitumor activity induced by 5-FU and IFNa
treatment. We have identified PKR as a kinase responsible for
5-FU-induced phosphorylation of the translation initiation factor
eIF2a, and of apoptosis induction, in a p53 independent manner
in colon and breast tumor cells. In addition, we show that cells
with PKR knockdown respond poorly to 5-FU treatment and are
not susceptible to the synergistic antitumor activity produced by
the 5-FU/IFNa combination.
Materials and Methods
Cell culture and reagents
PKR
+/+ and PKR
2/2 MEFs [32], and human colon HCT116
p53
+/+ and p53
2/2 cells [7], were kindly provided by M Esteban
(National Center of Biotechnology, Spain) and B. Vogelstein (Johns
Hopkins Oncology Center, USA), respectively. EIF2a
S/S and eIF2a
A/
A MEFs were kindly provided by C De Haro (Centro de Biologı ´a
Molecular Severo Ochoa, Spain) [33]. Human colon SW-480, T84,
RKO, cell lines and the human breast MCF7, MDA-MB-231, T47D
cell lines were obtained from American Type Culture Collection
(ATCC). PKR interference with short hairpin RNAs targeting PKR
(shRNA-PKR) were prepared as described below. Most of the cells
were maintained in DMEM medium supplemented with 10% FBS,
1% penicillin-streptomycin and 1% non-essential amino acid solution.
MDA-MB-231 cell line was cultured in DMEM/F12-Ham medium.
Exponentially growing cells were used for all experiments. 5-FU
(Sigma-Aldrich, F6627-1G) was dissolved in DMSO and stored at
220uC. For each experiment, the stock solutions were further diluted
in medium to obtain the desired concentrations. IFNalpha 2b (Intron
A) was obtained from Schering-Plough.
Cell survival assay
The effect of 5-FU on cell viability was assessed using the
sulforhodamine-B colorimetric assay (SRB). Aliquots of cell
suspension (3610
3 cells/well) were seeded onto 24-well plates and
incubated for 24 h. The cells were then treated with different
concentrations of 5-FU and with or without IFNa (50 IU/ml) in the
culture medium. Three days later, the wells were aspirated, fresh
medium and treatment were added, and cells were maintained for
three additional days. Thereafter, cells were processed as described
previously [34], using a Titertek Multiscan apparatus (Flow, Irvine,
CA, USA) at 492 nm. We evaluated linearity of the SRB assay with
cell number for each cell stock before each cell growth experiment.
The IC50 values were calculated from semi-logarithmic dose–
response curves by linear interpolation. All experiments were plated
in triplicate wells and were carried out at least twice.
Apoptosis analysis
Cells were plated in 6-well plates and maintained in the
incubator overnight. Cells were then induced for 48 hours with 5-
FU alone or in combination with IFNa (500 IU/ml). IFNa was
added 16 hours before the 5-FU.After 72 hours, cells were
trypsinized and analyzed using the kit TACS
TM Annexin V-FITC
(R&D System, TA4638), and the Annexin V-APC Apoptosis
detection kit (ebioscence, 88-8007-74) for cells expressing shRNA-
PKR. The samples were immediately processed with a FACScan
flow cytometer ‘‘VANTAGE’’ (Becton Dickson, San Jose, CA,
USA), using the flow cytometry service of the Scientific
Instrumental Center at the University of Granada.
Cell cycle analysis
Cells in exponential growth were plated on 6-well plates and
maintained in the incubator overnight. After that, cells were
induced for 24 and 48 hours with 10 mM 5-FU. Cells were
harvested, washed twice with PBS and fixed in 70% (vol/vol) cold
ethanol for up to 1 week. Cells were centrifuged, the pellet washed
once with PBS and re-suspended in 250 ml of Propidium Iodide
(PI) solution (100 ml/ml RNAsa, 40 ml/ml PI in PBS) for 30 min in
the dark at 37uC. The samples were immediately analyzed using a
FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Western Blot analysis
Cells were plated on 6-well plates in their respective medium.
After treatment, medium was removed and the cells were lysed in
Laemmli buffer. The protein sample was subjected to electropho-
resis, transferred onto nitrocellulose membranes (Bio-rad,162-
0115), and blocked in PBS containing 5% non-fat dry milk for 1 h
at room temperature. Primary antibodies used included a
polyclonal antibody to total human PKR provided by M Esteban
(National Center of Biotechnology, Spain), a polyclonal to
phospho- PKR (Thr 451) (Calbiochem, 527460), a polyclonal
antibody to phospho-eIF2a (Ser 51) (Invitrogen, 44–728,G), a
polyclonal antibody to phospho-p53 (Ser 15)(Cell signaling,
92845), a polyclonal antibody to full and cleaved caspase 3 (Cell
signaling, 8G10) and a monoclonal antibody to b-actin (Sigma,
A2228). Secondary antibodies used included anti-rabbit IgG
peroxidase conjugate (Sigma, A0545) and anti-mouse IgG
peroxidase conjugate (Sigma, A9044). Bands were visualized using
the ECL system (Amersham Pharmacia Biotech, UK).
Immunofluorescence
HCT116 p53
+/+ and p53
2/2 cells were mock-treated or treated
with 5 mM of 5-FU. At indicated times, cells were washed with
phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde,
and permeabilized (10 min, room temperature) with 0.1% Triton
X-100 in PBS, washed, and blocked with 20% bovine serum
albumin in PBS. Cells were incubated (2 h, room temperature) with
anti Phospho-PKR (Thr 451, Sigma) or anti- PKR antibody. Cover
slips were washed extensively with PBS and were further incubated
(1 h, 37uC) with DAPI and appropriate fluorescein-conjugated
isotype-specific secondary antibodies (Santa-Cruz). Images were
obtainedusingaBio-RadRadiance2100confocallasermicroscope.
Knocking down expression of human PKR in colon and
breast cancer cell lines by shRNA
To knockdown PKR, we obtained pGIPZ-lentiviral shRNAmir
vectors containing either non-silencing (NS) scrambled sequence
or three hairpin sequences targeting PKR (Open Biosystems,
RHS4430). The pGIPZ vectors expressed GFP to identify
transfected cells. MCF7, and HCT116 p53
+/+ and p53
2/2 cells
were transfected using Amaxa Cell line nucleofector kit V (Lonza
Cologne AG, VCA-1003) according to the manufacturers
protocol. To generate stable cell lines, two days after transfection,
we added puromycin (Invivogen, 58-58-2) at a concentration of
1 mg/ml to HCT116 cells and 3 mg/ml to MCF-7 cells to select
puromycin-resistant clones.
PKR Is a Key Molecular Target of 5-Fluorouracil
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Analysis
RNA direct isolation from tumor cell lines was performed by
RNeasy mini kit (Qiagen 74106), and sequentially complementary
DNA was generated using reverse transcription system (Promega
A3500), both strictly following the manufacturing instructions.
Real-time-PCR Quantitative was performed in 96-well plates with
an Applied Biosystems 7500 Real Time PCR System using
TaqMan Gene Expression Assays (Applied Biosystems) to quantify
the amplicons. Assays include PKR (Hs00169345_ml) and
GAPDH (Hs 99999905_ml) that was used as endogenous control
to normalize RNA concentration. PCR reaction was performed
following a protocol standardized by Applied Biosystems.
Results
PKR protein is activated by 5-FU
In order to explore if PKR is activated in response to 5-FU, we
first analyzed PKR phosphorylation and that of its natural
substrate eIF2a in several human colon and breast cancer cell
lines. 5-FU treatment induced PKR phosphorylation in colon
cancer SW-480 cells by 4 hours with a peak at 16 hours, whereas
in breast cancer MCF7 cells, PKR activation was already detected
4 hours after treatment. The translation initiation factor eIF2a
was phosphorylated in both cell lines in response to 5-FU
(Figure 1A). Importantly, we also observed an increase in the
PKR levels after 5-FU treatment. In contrast, we found one colon
(T84) and one breast cell line (T47D) where the PKR protein was
not detected and the basal level of eIF2a phosphorylation was
maintained during the 5-FU treatment. Moreover, IFNa treat-
ment upregulated PKR level in the tumor cell lines analyzed
except in T84 and T47D cells (Figure 1B). To confirm the
implication of PKR in eIF2a phosphorylation by 5-FU, we treated
mouse embryonic fibroblasts (MEFs) derived from wild type
(PKR
+/+) or PKR knockout (PKR
2/2) mice with the chemother-
apeutic agent. As shown in Figure 1C, 5-FU treatment induced the
upregulation and activation of the PKR protein as well as
phosphorylation of eIF2a, whereas in PKR
2/2-drug treated cells,
eIF2a phosphorylation was not detected. Moreover, in human
HCT116 colon cancer cell line in which PKR was knocked down
by RNA interference using shRNA-PKR, treatment with 5-FU did
not increase the basal level of eIF2a phosphorylation, while eIF2a
Figure 1. PKR activation upon 5-FU treatment in mouse and human cell lines. (A) SW-480, T84, MCF-7 and T47D cell lines were mock-
treated or treated with 10 mM of 5-FU during 4, 8, 16 and 24 hours. (B) SW-480, T84, MCF-7 and T47D cell lines were mock-treated or treated with
500 IU/ml of IFNa during 16 hours. (C) PKR
+/+ and PKR
2/2 MEFs and (D) HCT-116 colon cell line expressing shRNA against PKR (shRNA-PKR) or
expressing a control shRNA (shRNAc) as have been described in the Material and Methods, were mock-treated, treated with 500 IU/ml of IFNa during
16 hours or treated with 10 mM of 5-FU during 4, 8, 16 and 24 hours. Total proteins were extracted for immunoblot analysis using anti-phospho PKR,
anti- whole PKR, anti-phospho eIF2a, anti-whole eIF2a and anti-b-actin antibodies.
doi:10.1371/journal.pone.0023887.g001
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(Figure 1D). These data indicate that PKR is involved in the
biological mechanism exerted by 5-FU.
PKR plays an important role in the apoptosis induced by
5-FU
To demonstrate the role of PKR in cell cycle arrest and
apoptosis induced by 5-FU, PKR
+/+ and PKR
2/2 MEFs were
treated with 5-FU during 48 hours and analyzed by flow
cytometry. As shown in Figure 2A, 5-FU induces an accumulation
of both S and G2/M phases (13.2% and 27.8%, respectively) in
comparison with non-treated cells (3.1% in S phase and 7% in
G2/M phase) in PKR
+/+ MEFs. However, 5-FU treatment
induced in PKR
2/2 MEFs, a weak accumulation in both S and
G2/M phases (3.9% and 10.6%, respectively) in comparison with
non-treated cells (2.4% in S phase and 4.2% in G2/M phase).
Moreover, treatment with 10 mM of 5-FU in PKR
+/+ MEFs
induced considerable levels of apoptosis (Figure 2B). However,
apoptosis was not induced in 5-FU-treated PKR
2/2 cells. To
explore the role of eIF2a phosphorylation during 5-FU treatment,
we also analyzed MEFs expressing non phosphorylatable eIF2a
bearing the S51A mutation (i.e., eIF2a
A/A MEFs). We observed
that eIF2a
A/A MEFs were more susceptible to cell death by 5-FU
than PKR
+/+ MEFs (Figure 2B). Irinotecan-treatment was used as
a positive control of apoptosis induction [35].
To determine if in human cells PKR is also required for the
induction of apoptosis in response to 5-FU treatment, PKR was
down-regulated using shRNA against PKR in breast MCF-7
cancer cells and then, effectiveness of chemotherapeutic treatment
was analyzed and compared to that observed after the treatment of
the same cells expressing control dsRNA (Figure 2C). In fact,
apoptosis induced by 5-FU was significantly reduced in those cells
transfected with shRNA against PKR. It is interesting to note that
the colon cancer T84 cell line showed no apoptosis induction
when it was compared with the SW-480 colon cancer cell line in
response to 10 mM of 5-FU, and the breast cancer T47D cell line
showed a lower level of apoptosis compared with the MCF-7
breast cancer cell line, also treated with 10 mM of -FU (Figure 2D).
The results of Figure 2 showed the importance of PKR activation
in the apoptosis induced by 5-FU treatment.
Figure 2. PKR implication in the cell cycle arrest and in the apoptosis induced by 5-FU. (A) PKR
+/+ and PKR
2/2 MEFs were mock treated or
treated with 5 mM of 5-FU during 48 hours. Cell cycle was analyzed by flow cytometry after staining with PI. (B) PKR
+/+ MEFs, PKR
2/2 MEFs and
eIF2a
A/A MEFs were mock-treated, treated with 10 mM of 5-FU or with 100 mg/ml of Irinotecan during 48 hours. Thereafter treated cells were
trypsinized and analyzed by flow cytometry to AnnexinV positive determination. The asterisks ‘‘**’’ designates p,0.01 and the asterisk ‘‘*’’ designates
p,0.05 in mutated cells versus wild type cells. (C) MCF-7 breast cell line expressing shRNA against PKR (shRNA-PKR) or expressing a control shRNA
(shRNAc) and (D) colon and breast cancer cell lines SW-480, T84, MCF-7 and T47D, were mock-treated, or treated with 10 mM of 5-FU during 48 hours.
Subsequently, cells were trypsinized and analyzed by flow cytometry to AnnexinV positive determination. Values shown represent the mean of the
triplicate determinations calculated from a single experiment. Experiments were repeated at least three times. The asterisks ‘‘**’’ designates p,0.01 in
T84 versus SW-480 cells and T47D versus MCF-7 cells.
doi:10.1371/journal.pone.0023887.g002
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effectiveness of the 5-FU/IFNa-combined therapy
Taking into account the role of PKR in the cellular response to 5-
FU, we decided to analyze the 5-FU cytotoxic effect in cells lacking
or expressing PKR. Moreover, we hypothesized that the up-
regulation of the PKR level produced by IFNa could be involved in
the well known enhanced antitumor activity of this chemothera-
peutic drug [12]. To prove this assumption, cell survival was
determined in PKR
+/+ and PKR
2/2 MEFs treated with increasing
amounts of 5-FU, either alone or in combination with 50 IU/ml of
mouse IFNa. Our results showed that the cytotoxic effect of 5-FU
was higher in PKR
+/+ MEFs in comparison with the PKR
2/2
MEFs (Figure 3A). Moreover, mouse IFNa improved the cytotoxic
effect of 5-FU only in PKR
+/+ MEFs. The 5-FU concentration
necessary to produce 50% cell death (IC50 values) is shown in
Table 1. Similar experiments were carried out in human colon and
breast cancer cell lines (Figure 3B and C). The cytotoxic effect of 5-
FU was higher in those cell lines expressing PKR protein in
comparison with cells where PKR was not detected. In fact, the 5-
FU IC50 value was about 2-fold higher in T84 cells than in SW-480
cells (Table 1). Moreover, the 5-FU IC50 value in T47D cells was
about 4-fold higher than in MCF7 cells (Table 1). Therefore, cells
lacking PKR like T84 and T47D, were not affected by the addition
of human IFNa to the 5-FU treatment. In contrast, IFNa increased
the cytotoxic effect of 5-FU and reduced the 5-FU IC50 in SW-480
and MCF7 cells (Figure 3B and C; Table 1).
To confirm that through the induction of apoptosis PKR
activation is involved in the synergistic effect exerted by 5-FU/
IFNa combined treatment, we first set up the conditions by which
either, 5-FU or IFNa (i.e, 5 mM of 5-FU and 500 IU/ml of IFNa)
did not induce or induce low levels of apoptosis under our
experimental conditions in the different tumor cell lines (Figure 4).
When 5-FU and IFNa were combined, they were able to induce a
considerable level of apoptosis in colon and breast cancer cell lines
expressing the PKR protein. In contrast, those cells lacking PKR
(T84 and T47D cell lines) were not susceptible to the 5-FU/IFNa
induced apoptosis (Figure 4A). We also analyzed PKR
+/+ and
PKR
2/2 MEFs, and HCT116 cells expressing the shRNA control
or the shRNA against PKR. As shown in Fig. 4B, the apoptosis
induced by the combined 5-FU/IFNa treatment was significantly
reduced in PKR
2/2 MEFs compared with PKR
+/+ MEFs.
Interference of PKR in HCT116 cells also triggered a significant
reduction in apoptosis levels compared with the cells expressing
the shRNA control (Figure 4C). These results implicate PKR in
the cytotoxic effect of 5-FU and suggest that IFNa enhances this
effect, in part, through PKR up-regulation.
PKR activation by 5-FU occurs independently of p53
It has been previously described that the induction of apoptosis
in response to 5-FU was mediated by p53 [36]. Moreover, it has
been recently suggested that one of the functions of p53 is to
modulate PKR [37]. In order to determine if PKR activation and
apoptosis induction in response to 5-FU depend on p53, we
analyzed HCT116 p53
+/+ and HCT116 p53
2/2 cell lines. As
shown in Figure 5A, PKR and eIF2a were phosphorylated during
5-FU treatment in both cell lines. As index of apoptosis, the
cleavage of caspase 3 was produced during 5-FU treatment in both
cell lines at 16 and 24 hours post-treatment, and was detected
slightly during treatment with IFNa. However, the level of the
Figure 3. Cytotoxicity effect of 5-FU- and 5-FU/IFNa-combined therapy. (A) PKR
2/2 and PKR
+/+ MEFs, (B) Human colon cancer cell lines T84
and SW-480, and (C) Human breast cancer cell lines, T47D and MCF-7 were treated with increasing amounts of 5-FU alone (triangles) or in
combination with 50 IU/ml of IFNa (square) during 6 days as described in Material and Methods. The curve of cell survival was represented as
percentage referred to mock-treated cells. The concentration of 5-FU was different depending on cell lines sensitivity. Values shown represent the
mean of the triplicate determinations calculated from a single experiment. Cell survival was statistically different when comparing cell lines
expressing PKR with the cell lines deficient in PKR expression (p#0.05 in A and B; p#0.025 in C). Experiments were repeated at least three times.
doi:10.1371/journal.pone.0023887.g003
Table 1. IC50 values derived from curves analysis showed in
Fig. 3.
Cell Lines IC50(mM)
5-FU 5-FU+IFNa
MEFs PKR
+/+ 0.8860.06 0.6160.02
MEFs PKR
2/2 1.7460.05 1.7460.22
SW-480 3.7060.09 1.9060.20
T84 7.4860.60 7.8060.10
MCF-7 0.7160.04 0.5260.08
T47D 2.8060.10 2.7860.23
doi:10.1371/journal.pone.0023887.t001
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HCT116 p53
2/2 cells compared to the HCT116 p53
+/+ cells,
further supporting the known involvement of p53 in the apoptosis
induced by 5-FU [7]. In addition, PKR total level was also up-
regulated in the absence of p53 protein. As expected, PKR was up-
regulated in response to IFNa in both cell lines. In order to
determine whether up-regulation of PKR is at the transcriptional
level, the PKR mRNA was measured by real time PCR in
HCT116 p53
+/+ and p53
2/2 cells. Whereas IFNa treatment
produced about 4-fold induction in both cell lines, 5-FU treatment
did not induce significant up-regulation of PKR mRNA compared
to untreated cells (Figure 5B). As it has been previously shown, p53
is involved in the apoptosis induced by 5-FU as demonstrated by
comparing the apoptosis detected in HCT116 p53
+/+ and that
observed in p53
2/2 cells. However, down-regulation of the PKR
levels by shRNA interference was able to induce a reduction of the
apoptosis induced by 5-FU in both cells lines (Figure 5C).
Moreover we examined by immunofluorescence in HCT116
p53
+/+ and HCT116 p53
2/2 cells the level and localization of
phospho- PKR (p-T451) and total-PKR (Figure 6). In both cell
lines, the level of phospho -PKR increased during 5-FU treatment
and was localized in the cytoplasmic fraction and along the
cytoplasmic membrane. Total-PKR also increased during 5-FU
treatment in both cell lines and was located in the nucleus and in
the cytoplasm (Figure 6A and B). These results suggest the
relevance of PKR activation in 5-FU-apoptosis induction even in
the absence of p53.
Discussion
Increased interest has been focused on the identification of new
clinical markers with regard to chemotherapeutic response and
prognosis in cancer. Since alterations in the mediators of 5-FU-
induced apoptosis may account for chemoresistance, the identifi-
cation of new targets involved in the 5-FU-induced apoptosis is of
significant clinical interest. Recently, it has been shown that PKR
plays an important role in the induction of apoptosis by
doxorubicin and etoposide [37,38].
In this study we have investigated the role of PKR in the cellular
response to 5-FU. Our results demonstrated that PKR was
markedly up-regulated and activated during the 5-FU treatment in
MEFs and in human colon and breast cancer cell lines, triggering
eIF2a phosphorylation (Figure 1). Significantly, after PKR
activation there was a marked reduction in PKR phosphorylation
levels at 24 h post-treatment (Figure 1A). This effect could be due
to phosphatase PP-1 regulation [39] and/or by proteolytic
degradation of active PKR mediated by caspase activation during
the apoptosis induction [40,41].
We have found that the colon T84 cancer cell line and the
breast T47D cancer cell line did not express PKR protein even in
the presence of IFNa (Figure 1B). Curiously, Jurkat cells express a
Figure 4. Apoptosis induced in MEFs and in human colon and breast cancer cell lines during the 5-FU/IFNa-combined treatment. (A)
5610
5 human colon and breast cancer cells, (B)5 610
5 PKR
+/+ or PKR
2/2 MEFs and (C)5 610
5 HCT-116 colon cancer cells expressing shRNA against
PKR or control shRNA, were mock-treated, treated with 500 IU/ml of IFNa, treated with 5 mM of 5-FU or treated with combination of IFNa plus 5-FU
during 48 hours. Thereafter treated cells were trypsinized and analyzed by flow cytometry to Annexin V positive determination. The asterisks ‘‘**’’
designates p,0.01 and the asterisk ‘‘*’’ designates p,0.05 in cells with PKR knockdown versus cells expressing PKR.
doi:10.1371/journal.pone.0023887.g004
PKR Is a Key Molecular Target of 5-Fluorouracil
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23887truncated version of PKR with decreased activity [18]. Aberrant
activation of PKR has been reported in numerous neurodegen-
erative diseases and cancer [17,18,19,20]. Loss of expression of
PKR has recently been found in immunohistochemical analysis of
tumor samples from lung [42]. However, if a truncated version of
PKR or the absence of PKR protein expression also occurs in
other solid tumors has not yet been analyzed.
Continued activation of PKR finally triggers cell cycle arrest
and/or the apoptosis phenomena [43,44]. The cell cycle arrest
induced by 5-FU in MEFs PKR
+/+ was not detected in absence of
PKR protein (Figure 2A). Similar results have been reported for
heparin-treatment of PKR
2/2 MEFs which were markedly
insensitive to its antiproliferative actions [45]. In fact, PKR acts
as a potent negative regulator of cell growth by the attenuation of
cell cycle progression when is over-expressed in yeast or
mammalian cells [44,46]. As shown here, PKR induces apoptosis
in response to 5-FU treatment since PKR knockdown decreased
significantly this cell death phenomenon (Figure 2B, C and D). It is
well established that eIF2a phosphorylation correlates with a
translational block and consequently leads to inhibition of protein
synthesis, providing the cell with the opportunity to elicit adaptive
responses [40,43]. However, although prolonged induction of
eIF2a phosphorylation is mainly proapoptotic [43,47], transient
induction of eIF2a phosphorylation functions mostly cytoprotec-
tively through the activation of pathways that promote cell survival
such as the phosphatidylinositol-3 kinase (PI3K) and nuclear factor
kB (NF-kB) pathways [48,49]. Using MEFs expressing a non-
phosphorylatable form of eIF2a (eIF2a
A/A MEFs), we found
during 5-FU treatment higher levels of apoptosis than control cells.
This result suggests that similarly as it has been described for
Figure 5. PKR regulation by 5-FU treatment in HCT116 p53
+/+ and HCT116 p53
2/2 cells. (A) HCT116 p53
+/+, HCT116 p53
2/2 cells were
mock-treated, treated with 500 IU/ml of human IFNa during 16 hours, or treated with 10 mM of 5-FU during 4, 8, 16 and 24 hours. Total proteins were
extracted for immunoblot analysis using anti whole p53, PKR, anti phospho PKR, anti whole PKR, anti phospho eIF2a, anti whole eIF2a, anti cleaved
caspase-3, and anti b-actin antibodies. (B) HCT116 p53
+/+, HCT116 p53
2/2 cells were mock treated or treated with 10 mM of 5-FU or 500 IU/ml of IFNa
during 16 hours. Expression of endogenous mRNA of PKR was analyzed by real-time RT-PCR (means6SEM, n=3) as described in material and
methods. (C) HCT116 p53
+/+, HCT116 p53
2/2 cells expressing shRNA against PKR or control shRNA mock-treated, or treated with 10 mM of 5-FU
during 48 hours. After treatment cells were trypsinized and analyzed by flow cytometry to AnnexinV positive determination. Total proteins of both
cell lines were extracted for immunoblot analysis using anti whole PKR and b-actin antibodies. The asterisks ‘‘**’’ designates p,0.01 in HCT116 p53
+/+
cells expressing shRNA against PKR versus cells expressing the control shRNA. The asterisk ‘‘*’’ designates p,0.05 in HCT116 p53
2/2 cells expressing
shRNA against PKR versus cells expressing the control shRNA.
doi:10.1371/journal.pone.0023887.g005
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ylation induced by 5-FU would have a protective role prior to the
induction of apoptosis. PKR is involved in numerous pathways
activated during cellular stress. Although the direct substrate of
PKR is the translation initiation factor eIF2a, PKR has wide
substrate specificities and might also act through protein-protein
interactions [16,51]. In fact, this kinase acts as a signal integrator
for stress-activated protein kinase pathways, leading to stimulation
of JNK, p38 and ATF-3 and the induction of apoptosis in response
to various stimuli such as dsRNA, LPS, TNF-a and doxorubicin
[38,52,53,54,55].
In correlation with the different levels of apoptosis and PKR
expression, the cytotoxic effect produced by 5-FU in cells with
PKR knockdown was significantly lower that in cells expressing
PKR (Figure 3 and Table 1), suggesting the implication of PKR
activation in response to 5-FU treatment. Moreover, several
studies showed the effectiveness in vitro and in vivo of combined
therapy with IFNa and 5-FU [56,57,58]. Various mechanisms
have been reported to be involved in the synergistic effect of 5-
FU/IFNa combination therapy, such as reduced 5-FU clearance,
and increased amount of FdUMP metabolite together with
increased inhibition of thymidylate synthase [57,59]. Furthermore,
analysis in hepatocarcinoma cell lines revealed the importance of
apoptosis in the improvement of antitumor activity of 5-FU by
IFNa. More recent studies involved p27Kip1, Fas/FasL and
TRAIL as mediators of the improvement in apoptosis during drug
combination [58,60,61]. Our results suggest that the up-regulation
of PKR induced by IFNa treatment could be also involved in the
effectiveness of combined therapy (Figure 3, Table 1). Cells with
PKR knockdown treated with IFNa/5-FU were less affected than
cells expressing PKR, as shown by the cytotoxic analysis and levels
of apoptosis detected by the combined 5-FU/IFNa treatment
(Figure 3, Table 1 and Figure 4). Therefore, our results suggest
that PKR protein could be included into the group of mediators of
5-FU action, and that the antitumor activity produced by 5-FU
should be further enhanced when PKR is induced by IFNa.
The p53 tumor suppressor has been reported as an important
protein involved in 5-FU-induced apoptosis [3,7]. However,
experiments showed that apoptosis can also occur in mutant p53
cell lines by a mechanism still unknown [6]. We have shown here
that PKR is activated in absence of p53 expression and PKR
knockdown decreased 5-FU- mediated apoptosis in HCT116
p53
+/+ cells and almost prevented apoptosis in HCT116 p53
2/2
cells. (Figure 5). These results suggest the importance that both
p53 and PKR play in the 5-FU-induced apoptosis, and the
relevance acquired by PKR in tumor cells where p53 is mutated.
Since the association of p53 tumor alterations with patient
prognosis and response to adjuvant chemotherapy has been
widely studied, with contradictory findings [62,63,64], the analysis
of additional prognostic and preventive molecular markers such as
PKR could be of clinical interest.
Figure 6. Localization of phospho-PKR and total-PKR in HCT116 p53
+/+ and HCT116 p53
2/2 cells. (A) HCT116 p53
+/+ cells and (B) HCT116
p53
2/2 cells were mock treated or treated with 5 mM of 5-FU. At the indicated times cells were fixed and processed for immunofluorescence analysis
by confocal microscopy as described in Material and Methods using antibodies against phospho-PKR (green) and anti- whole PKR (green) and DAPI
for staining nuclei (blue).
doi:10.1371/journal.pone.0023887.g006
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promoter in response to genotoxic damage [37] led us to examine
whether the up-regulation of PKR protein levels detected in
response to 5-FU treatment (Figure 5 and Figure 6) is due to a
transcriptional regulation mediated by p53. Our results showed
that the increase in PKR protein level in response to 5-FU
treatment was partially regulated by p53 since level of PKR
increased in absence of p53, although to a lesser extent (Figure 5A
and Figure 6). The mRNA analysis suggested that PKR protein
up-regulation was not due to a transcriptional phenomenon
(Figure 5C). Therefore, similar to what has been described for the
molecular targets of 5-FU, thymidylate synthase protein, and even
the p53 protein, PKR might undergo a post-transcriptional
regulation during 5-FU treatment [65,66,67]. Although PKR
promotes the proteosomal degradation of p53 through the
glycogen synthase kinase 3 [68], if PKR stability protein is also
regulated by p53 is still unknown.
To summarize, our results demonstrate that PKR is a 5-FU
molecular target that plays an important role in the cytotoxic effect
of 5-FU at least, in part, through induction of cell death by
apoptosis in a p53 -independent manner. These results suggest the
clinical importance that the PKR status could play in response to
chemotherapy based on 5-FU. Moreover, the effectiveness of 5-FU
cytotoxic activity induced by IFNa, especially in cancer cells
expressing a mutated form or lacking p53, but with a functional
PKR, might have relevant clinical application in patients.
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